Théa and ProQR Therapeutics sign a new partnership
Théa and ProQR Therapeutics sign a new partnership
Menu
©Zhiguo He
Théa and ProQR Therapeutics sign a new partnership
Théa and Olix Pharmaceuticals sign a new partnership
Théa and Gallimedix, Inc sign a new partnership
Théa Open Innovation and CURACLE sign a new partnership
Théa and Coave Therapeutics announce their partnership
Théa and Coave Therapeutics announce their partnership
Théa and Coave Therapeutics sign an exclusive licensing, co development and commercialization agreement
Théa and Coave Therapeutics announce their partnership
Théa and Nevakar sign an exclusive licensing agreement for a unique therapeutic solution in the treatment of myopia progression in children.
Théa Open Innovation signs an exclusive Licensing Agreement for the rights on Ripple Therapeutics Corporation lead product, IBE-814 for North America and Europe.
Feel free to contact us to submit your project or ideas.
Théa Open Innovation
12 rue Louis-Blériot
63017 CLERMONT-FERRAND cedex
FRANCE
Tel. +33 (0)4 73 98 14 36
© Théa Open Innovation 2024 | Personal data protection | Terms & conditions | Legal terms | Site Map